Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5CBQ9)

Drug Name

Cyclo(1,10)H-EIYDPGDDIK-OH Drug Info

Synonyms

CHEMBL506798

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell surface antigen CD2 (CD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siplizumab	DM75RFJ	Lymphoma	2A80-2A86	Phase 2	[2]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[3]
Cyclo(1,12)PenIYDTKGKNVLC-OH	DMVDS8B	Discovery agent	N.A.	Investigative	[4]
Pen(Acm)AQFRKEKETFC(Acm)-OH	DM81AWU	Discovery agent	N.A.	Investigative	[4]
Cyclo(1,11)H-ESIYDPGDDIK-OH	DM4A1TF	Discovery agent	N.A.	Investigative	[1]
Cyclo(1,10)EIYDPGDDIK	DMFUG05	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36.
2	Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4	Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49.